However, studies investigating Cx43 in breast and breast tumor cells often utilize drugs that globally inhibit gap junction activity, affecting not only Cx43 but also other connexins, or employ constructs altering mRNA and Cx43 protein expression levels. The gene discussed is GJA1; the disease is breast neoplasm.